LivaNova PLC $LIVN Shares Sold by Great Lakes Advisors LLC

Key Points

• Great Lakes Advisors LLC reduced its stake in LivaNova PLC by 3.6%, now holding approximately 269,476 shares valued at about $10.6 million.
• LivaNova has seen a positive trend in analyst ratings, with several upgrades, including an upgraded rating to "strong-buy" from Wall Street Zen and price targets ranging from $55.00 to $64.00.
• The company's recent quarterly earnings exceeded expectations, reporting $1.05 EPS against an anticipated $0.84, with revenues reaching $352.5 million.

Great Lakes Advisors LLC reduced its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 3.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 269,476 shares of the company's stock after selling 9,927 shares during the period. Great Lakes Advisors LLC owned about 0.49% of LivaNova worth $10,585,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. UMB Bank n.a. boosted its holdings in shares of LivaNova by 340.5% in the 1st quarter. UMB Bank n.a. now owns 837 shares of the company's stock valued at $33,000 after acquiring an additional 647 shares during the last quarter. CWM LLC boosted its holdings in LivaNova by 52.3% during the first quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after buying an additional 299 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in LivaNova by 415.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,469 shares of the company's stock worth $58,000 after buying an additional 1,184 shares in the last quarter. Central Pacific Bank Trust Division boosted its holdings in LivaNova by 7.0% during the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after buying an additional 290 shares in the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new stake in LivaNova during the fourth quarter worth $241,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Down 2.0%

Shares of NASDAQ LIVN traded down $1.12 during midday trading on Friday, hitting $56.22. The company's stock had a trading volume of 571,347 shares, compared to its average volume of 556,958. The business's fifty day simple moving average is $49.83 and its two-hundred day simple moving average is $44.09. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. LivaNova PLC has a 1 year low of $32.48 and a 1 year high of $58.91. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of -14.45 and a beta of 0.96.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. The firm had revenue of $352.50 million for the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a negative net margin of 16.13% and a positive return on equity of 14.57%. The firm's revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.93 earnings per share. On average, equities analysts predict that LivaNova PLC will post 2.85 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on LIVN shares. Barclays increased their price target on shares of LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a research note on Tuesday, May 20th. Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research report on Wednesday, September 3rd. Finally, Wall Street Zen upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, LivaNova currently has a consensus rating of "Buy" and a consensus target price of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.